AITechNodeabout 2 months ago
Antibody discovery platform Immunocan closes RMB250 million Series A
1 min read
Shanghai-based Immunocan closed a RMB250 million Series A led by Vivo Capital. Funds will advance gene-edited animal platforms, commercialize a fully human antibody rabbit platform, build an AI-driven antibody drug screening platform, and expand the team. The company was founded in 2020.
Level
Hype check
Tap to vote and see what everyone thinks.
